Brendan is a co-founder of Inhibrx and serves as its Chief Scientific Officer and Executive Vice President of Corporate Strategy. Brendan heads research, overseeing several key functional areas spanning discovery to therapeutic development. Brendan is also a member of Inhibrx’s Board of Directors. In addition, he has critical responsibilities in corporate strategy and operations. Prior to founding Inhibrx, he was a Research Investigator in the biotherapeutics group at the Genomics Institute of the Novartis Research Foundation (GNF). He conducted his graduate research at the Sanford-Burnham-Prebys Medical Discovery Institute. Brendan received his Ph.D. in molecular pathology from the University of California, San Diego School of Medicine.